Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)

Diabetic Medicine

Volumn 26, Issue 12, 2009, Pages 1242-1249

  Scheen, A J ^a   Tan, M H ^b   Betteridge, D J ^c   Birkeland, K ^d   Schmitz, O ^e   Charbonnel, B ^f  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d AKER UNIVERSITY HOSPITAL   (Norway)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f Clinique d'Endocrinologie Hotel Dieu CHU de Nantes   (France)

Author keywords

Combination therapy; Metformin; Pioglitazone; Sulphonylurea; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EDEMA; FEMALE; FOLLOW UP; FRACTURE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VASCULAR DISEASE; WEIGHT GAIN;

ADMINISTRATION, ORAL; AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 70549103600     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02857.x     Document Type: Article

References (25)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). The UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999 281 : 2005 2012.
2. Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998 55 : 225 236.
3. Krentz AJ, Bailey CJ. Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs 2005 65 : 385 411.
4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. American Diabetes Association; European Association for the Study of Diabetes Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 : 193 203.
5. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Lancet 2005 366 : 1279 1289.
6. Betteridge DJ, DeFronzo RA, Chilton RJ. PROactive: time for a critical appraisal. Eur Heart J 2008 29 : 969 983.
7. PROactive. Statistical Analysis Plan. Available at http://www.proactive- results.com Last accessed 22 December 2008.
8. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009 32 : S13 S61.
9. International Diabetes Federation (European Region), Brussels. A desktop guide to Type 2 diabetes. Diabet Med 1999 16 : 716 730.
10. Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B on behalf of the PROactive investigators. Long-term glycaemic control with metformin-sulfonylurea-pioglitazone triple therapy in the PROactive Study (PROactive 14). Diabet Med 2009 26 : 1033 1039.
11. Special issue. Cardiovascular benefits of metformin. Diabetes Metab 2003 29 : 6S5 6S122.
12. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 865.
13. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L Digami 2 Investigators. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008 29 : 166 176.
14. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005 28 : 600 606.
15. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355 : 2427 2443.
16. UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998 21 : 87 92.
17. Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005 28 : 544 550.
18. Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005 48 : 1093 1104. (Pubitemid 40909644)
19. Seufert J, Urquhart R. Two-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with Type 2 diabetes. Diabetes Res Clin Pract 2008 29 : 453 460.
20. Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007 24 : 626 634.
21. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005 28 : 2673 2679. (Pubitemid 43951158)
22. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus. The AACE System of Intensive Diabetes Self-Management - 2002 Update. Available at http://www.aace.com/pub/pdf/ guidelines/diabetes-2002.pdf Last accessed 22 December 2008.
23. Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2006 66 : 85 109.
24. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008 31 : 845 851.
25. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive Study (PROactive 08). Diabetes Care 2007 30 : 2773 2778.